(Reuters) -Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

Dr Reddy's reported Rs 1,417 crore net profit in Q1 FY26, driven by new launches and price hikes; firm outlines global ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

Dr. Reddy’s Laboratories ( NYSE: RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo ...

Dr Reddy’s kicks off India’s big pharma earnings season with a narrow profit miss. The pharmaceutical company reported a ...

Pharmaceutical major Dr. Reddys Laboratories reported its financial results for the first quarter (Q1) of FY26 on Thursday, ...

With this launch by Dr. Reddy’s, India becomes the third country in the world after China and the United States to receive access to this next generation PD-1 inhibitor 1. Dr.

Revenue rose 9% to 69.03 billion rupees, led by a jump in the key global generics segment. North America business, Dr Reddy's largest contributor, grew 13%, while sales in India and Europe rose 3% ...